A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Inclusion Criteria:

1. Signed informed consent prior to participation in the extension study.

2. Participants must have participated in either one of the two NEPTUNUS core studies,CVAY736A2301 or CVAY736A2302, and must have completed the entire treatment up toWeek 48 without treatment discontinuation in core NEPTUNUS studies.

3. In the judgement of the Investigator, participants must be expected to clinicallybenefit from continued ianalumab therapy.

Exclusion Criteria:

1. Use of therapies excluded by the NEPTUNUS-1 and NEPTUNUS-2 study protocols (seeNEPTUNUS studies protocols exclusion criteria in Section 5.2 for details).

2. Plans for administration of live vaccines during the study period.

3. Pregnant or nursing (breastfeeding) women, where pregnancy is defined as the stateof a female after conception and until the termination of gestation, confirmed by apositive human Chorionic Gonadotropin (hCG) laboratory test.

4. Women of child-bearing potential (WOCBP), defined as all women physiologicallycapable of becoming pregnant, from menarche until becoming post-menopausal, unlessthey have had surgical bilateral oophorectomy (with or without hysterectomy), totalhysterectomy or bilateral salpingectomy at least six weeks before taking studytreatment. In the case of oophorectomy alone, the reproductive status of the womanneeds to have been confirmed by follow-up hormone level assessment. Women areconsidered post-menopausal if they have had 12 months of natural (spontaneous)amenorrhea with an appropriate clinical profile (e.g., hormonal profile confirmingmenopause and/or age-appropriate history of vasomotor symptoms). WOCBP are excluded unless they are using highly effective methods of contraception (failure rate < 1% per year) while taking study treatment during dosing and for 6months after stopping of investigational drug. Highly effective contraceptionmethods include:

• Total abstinence (when this is in line with the preferred and usual lifestyleof the participant. Periodic abstinence (e.g., calendar, ovulation,symptothermal, post- ovulation methods) and withdrawal are not acceptablemethods of contraception.

• Bilateral tubal occlusion or bilateral tubal ligation (at least six weeksbefore taking study treatment).

• Sterilization (vasectomy) of male partner (s) of the female participant atleast 6 months prior to screening provided partner(s) has(have) receivedmedical confirmation of surgical process.

• Use of hormonal contraception methods:

• Combined (estrogen and progestogen-containing) hormonal contraceptionassociated with inhibition of ovulation; oral, intravaginal or transdermal.

• Progestogen-only hormonal contraception associated with inhibition ofovulation: oral, injectable or implantable.

• Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) Incase of use of oral contraception women should have been stable on the samepill for a minimum of 3 months before taking study treatment. Contraception should be used in accordance with locally approved prescribinginformation of concomitant medications administered. If local regulations are more stringent than the contraception methods listed above,local regulations apply and will be described in the informed consent form (ICF).

5. United States (and other countries, if male contraception is locally required):Sexually active males, unless they agree to use barrier protection duringintercourse with a woman of child-bearing potential, while taking study treatment.As condom use alone has a reported failure rate exceeding 1% per year, it isrecommended that female partners of male study participants use a second method ofbirth control. Although ianalumab is not teratogenic and/or genotoxic, and nottransferred to semen, male contraception is required, as requested by FDA.

Globally, for all sexually active males, contraception should be used in accordance with the locally approved prescribing information of concomitant medications administered.